IRIS
BELCARO, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.226
AS - Asia 6.343
EU - Europa 5.933
SA - Sud America 1.225
Continente sconosciuto - Info sul continente non disponibili 507
AF - Africa 116
OC - Oceania 46
AN - Antartide 1
Totale 27.397
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.824
SG - Singapore 2.428
CN - Cina 1.661
BR - Brasile 955
UA - Ucraina 917
IE - Irlanda 890
IT - Italia 866
RU - Federazione Russa 697
VN - Vietnam 697
TR - Turchia 677
SE - Svezia 571
GB - Regno Unito 538
FR - Francia 429
DE - Germania 399
IN - India 255
FI - Finlandia 200
CA - Canada 155
HK - Hong Kong 147
AR - Argentina 122
PL - Polonia 116
BD - Bangladesh 70
MX - Messico 69
ID - Indonesia 66
ES - Italia 52
EC - Ecuador 45
JP - Giappone 43
NL - Olanda 42
AU - Australia 40
BE - Belgio 40
KR - Corea 39
ZA - Sudafrica 34
CR - Costa Rica 33
AT - Austria 31
TH - Thailandia 31
IQ - Iraq 28
PK - Pakistan 28
CO - Colombia 27
VE - Venezuela 27
PH - Filippine 26
HN - Honduras 25
JM - Giamaica 25
CZ - Repubblica Ceca 24
IL - Israele 23
IR - Iran 22
CH - Svizzera 21
PY - Paraguay 21
TT - Trinidad e Tobago 19
SA - Arabia Saudita 17
GT - Guatemala 16
PT - Portogallo 16
EG - Egitto 15
TN - Tunisia 15
TW - Taiwan 15
NI - Nicaragua 14
EU - Europa 13
JO - Giordania 13
SV - El Salvador 13
CL - Cile 11
MY - Malesia 11
PE - Perù 11
PR - Porto Rico 11
SC - Seychelles 11
GR - Grecia 10
LT - Lituania 10
MA - Marocco 10
CW - ???statistics.table.value.countryCode.CW??? 9
UZ - Uzbekistan 9
RO - Romania 8
SK - Slovacchia (Repubblica Slovacca) 8
AE - Emirati Arabi Uniti 7
HR - Croazia 7
DK - Danimarca 6
DZ - Algeria 6
EE - Estonia 6
GP - Guadalupe 6
KE - Kenya 6
NP - Nepal 6
NZ - Nuova Zelanda 6
BG - Bulgaria 5
KZ - Kazakistan 5
SI - Slovenia 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
KW - Kuwait 4
BB - Barbados 3
ET - Etiopia 3
LU - Lussemburgo 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
CG - Congo 2
GA - Gabon 2
LB - Libano 2
MK - Macedonia 2
PA - Panama 2
SO - Somalia 2
TG - Togo 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 26.884
Salva come PNG Salva come JPEG
Città #
Singapore 1.713
Jacksonville 1.168
San Jose 979
Chandler 907
Dublin 883
Ashburn 645
Council Bluffs 509
Dallas 448
Princeton 434
Izmir 357
Beijing 348
Nanjing 338
Southend 334
Santa Clara 255
Ho Chi Minh City 254
Los Angeles 230
Wilmington 189
Cambridge 186
Altamura 183
Hanoi 158
New York 148
Ann Arbor 129
Tongling 128
Hong Kong 122
Nanchang 118
Dearborn 110
North Bergen 95
Atlanta 94
The Dalles 94
Buffalo 87
Moscow 85
Phoenix 78
Boardman 73
São Paulo 72
Redondo Beach 66
Kraków 65
Shenyang 63
Orem 58
Hebei 56
Milan 52
Columbus 50
San Francisco 50
Rome 49
Denver 46
Tianjin 46
Kunming 45
Woodbridge 45
Brooklyn 44
Seattle 42
Munich 41
Da Nang 40
Jiaxing 40
London 40
Montreal 40
Houston 38
Norwalk 38
Warsaw 38
Chicago 36
Boston 35
Catania 35
Tokyo 34
Changsha 31
Brussels 30
Washington 30
Chennai 28
Frankfurt am Main 28
Memphis 28
Rio de Janeiro 28
Kimball 27
Toronto 27
Haiphong 26
San José 23
Chieti 22
Mexico City 22
Naples 22
Ankara 21
Curitiba 21
Falls Church 21
Hangzhou 21
Mount Pleasant 21
Sydney 21
Vienna 20
Las Vegas 19
Manchester 19
Amsterdam 18
Guangzhou 18
Hefei 18
Istanbul 18
Mumbai 18
Johannesburg 17
Lanzhou 17
Philadelphia 17
Belo Horizonte 16
Brno 16
Grevenbroich 16
Helsinki 16
Kingston 16
Biên Hòa 15
Quito 15
San Mateo 15
Totale 14.005
Salva come PNG Salva come JPEG
Nome #
Supplementary prevention and management of asthma with quercetin phytosome: a pilot registry 686
Xerostomia: prevention with Pycnogenol® supplementation: a pilot study. 559
Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study). 446
Venoruton vs Daflon: evaluation of effects on qualità of life chronic venous insuffciency 368
The COFU3 Study. Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress 365
Pycnogenol may alleviate adverse effects in oncologic treatment 340
Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study 320
Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: A randomized clinical study. 301
Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study 276
Improvement of common cold with Pycnogenol®: a Winter registry study 243
Robuvit® (Quercus robur extract) supplementation in subjects with chronic fatigue syndrome and increased oxidative stress. A pilot registry study 224
Beanblock® (standardized dry extract of Phaseolus vulgaris) in mildly overweight subjects: a pilot study. 208
Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit® 201
Prevention of edema in long flights with Pycnogenol 192
Aescin and microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. 181
Prevention of influenza episodes with colostrum compared with vaccination in healthy and high-risk cardiovascular subjects: the epidemiologic study in San Valentino 180
Lady Prelox® improves sexual function in post-menopausal women 179
A short-term vs a long-term infusion plan. A 20-week, European randomized trial. Analysis of efficacy and costs. 178
Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo 177
An open, supplement, registry study Arborvitae (R) for prevention of arthrosis-related pain during exercise 176
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin. 174
Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension 171
The lung in systemic vasculitis: Radiological patterns and differential diagnosis 171
Robuvit® and endurance in triathlon: improvements in training performance, recovery and oxidative stress 167
Centella asiatica (Centellicum®) facilitates the regular healing of surgical scars in subjects at high risk of keloids. 167
Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma - a registry study 166
Robuvit®: improvement of fatigue in medical convalescence. 165
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment. 163
Improvement in symptoms and cochlear flow with pycnogenol in patients with Meniere's disease and tinnitus 162
Incidence of perioperative stroke during peripheral revascularization or aortocoronary bypass in patients with carotid bruit and stenosis 161
Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings 161
Prevention of edema and flight microangiopathy with Venoruton (HR), (0-[beta-hydroxyethyl]-rutosides) in patients with varicose veins 158
Aescin: microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. 158
A natural pharma standard supplement formulation to control treatment-related toxicity and oxidative stress in genitourinary cancer: a preliminary study 158
Topical heparin: New observations 155
Mononucleosis-related fatigue: supplementary management with Robuvit®. 155
Bilberry extracts are not created equal: the role of non anthocyanin fraction. Discovering the "dark side of the force" in a preliminary study 154
PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial 154
Management of functional, hepatic damage after chemotherapy with Liverubin (pharma-standard silymarin). 152
Postoperative pulmonary infections: role of antibiotic treatment 151
[Breast cancer. Epidemiology and other factors related to incidence in various populations]. 148
Prevention of recurrent venous thrombosis and post-thrombotic syndrome. 148
[European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication] 147
Jet-lag: prevention with Pycnogenol. Preliminary report: evaluation in healthy individuals and in hypertensive patients 147
Treatment of Osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of Signs, Symptoms,Physical Performance and Vascular Aspects 147
Effects of pycnogenol on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study. 147
Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial 146
Clinical evaluation of defibrotide in the treatment of arterial and venous vascular disease. A preliminary report. 145
Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms. 144
Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella Asiatica: a clinical prospective randomized trial with a microcirculatory model. 142
Management of superficial vein thrombosis and thrombophlebitis: status and expert opinion document. 142
Treatment of ankle sprain in patients with vascular diseases of the lower limbs 142
Behçet syndrome: effects of Pycnogenol® supplementation during regression phases. 141
Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. 140
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. 140
TECA (Titrated Extract of Centella Asiatica): new microcirculatory, biomolecular, and vascular application in preventive and clinical medicine. A status paper. 140
Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol 139
Pycnogenol treatment of acute hemorrhoidal episodes. 139
Temporary kidney dysfunction: Robuvit® supplementation in initial, transient kidney insufficiency and micro-macro albuminuria 139
[Comparison of netilmicin with other aminoglycosides in severe surgical infections]. 138
Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study. 137
Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®). 137
Pycnogenol®+Centellicum®, post-stent evaluation: prevention of neointima and plaque re-growth 137
Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. 136
Circulating endothelail cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: improvement with venoruton 136
A controlled study shows daily intake of 50 mg of French Pine Bark Extract (Pycnogenol®) lowers plasma reactive oxygen metabolites in healthy smokers. 136
Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. 135
5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-(β-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry 135
Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study 135
Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. 134
Superficial vein thrombosis (SVT), diffusion of thrombotic diseases, and increased global thrombogenicity: SVT as an important spy disease indicating environmental contamination by estrogens - Introduction 134
Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study. 132
Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome 132
Mirtogenol® supplementation in association with dorzolamide-timolol or latanoprost improves the retinal microcirculation in asymptomatic patients with increased ocular pressure 132
HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. 131
O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study 130
Thyroid cysts treatment with the sclerosing agent Atossiclerol. Long-term (5 to 15 years) follow-up. 130
Microcirculatory effects of Viatromb® spray gel heparin in chronic venous insufficiency: Evaluation of TcPO2 and PCO2 - A product evaluation study 129
Management of uncomplicated ankle sprains with topical or oral ketoprofen treatment. A registry study 129
Pycnogenolà supplementation improves health risk factors in subjects with metabolic syndrome 128
Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. 127
Improvement in signs and symptoms in psoriasis patients with Pycnogenol® supplementation. 127
Capillary filtration in venous hypertension: evaluation with the vacuum suction chamber device and strain-gauge plethysmography. 126
Efficacy and Safety of Meriva, a Curcumin-phosphatidylcholine Complex, during Extended Administration in Osteoarthritis Patients 126
[Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs]. 126
Prevention of diffuse, minimal lymphatic "retention" with Robuvit®: a concept, supplement registry study 126
A plaster combining diclofenac and heparin: microcirculatory evaluation in 2 models of high-perfusion microangiopathy 125
Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. 123
Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10 year follow-up study (the CAFES-CAVE Study). 122
Cramps and Muscular Pain: Prevention with Pycnogenol((R)) in Normal Subjects, Venous Patients, Athletes, Claudicants and in Diabetic Microangiopathy 122
The value of segmental pressure measurement in the assessment of peripheral vascular disease. 122
Venous and diabetic ulcerations: management with topical multivalent silver oxide ointment. 122
Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. 122
A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment 121
Local heparin, superficial vein thrombosis 121
Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extract 121
Treatment of Diabetic Microangiopathy and Edema with Total Triterpenic Fraction of Centella Asiatica: A Prospective, Placebo-Controlled Randomized Study. 120
Microcirculatory Effects of Total Triterpenic Fraction of Cenetlla asiatica in Chronic Venous Hypertension: Measurement by Laser Doppler, TcPo2-CO2, and Leg Volumetry 120
[Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin] 120
Improvement of common cold with Pycnogenol®: a Winter registry study. 120
Totale 17.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022649 0 0 0 0 77 25 19 64 67 17 100 280
2022/20232.700 269 402 156 284 231 565 177 174 276 26 88 52
2023/20241.133 88 50 65 24 47 283 332 38 22 48 33 103
2024/20253.352 258 681 528 55 78 93 64 147 386 140 278 644
2025/20267.276 481 297 939 1.341 542 365 880 495 719 534 441 242
2026/20275.331 840 1.639 927 1.520 405 0 0 0 0 0 0 0
Totale 27.397